万达生物制药 VNDA 深 沪
等待开盘 06-26 09:30:00 美东时间
5.845
-0.055
-0.93%
华盛通- 最 高6.11
- 今 开5.84
- 成交量 46.57万股
- 最 低 5.82
- 昨 收 5.90
- 总市值 33.02万
- 52周最高 9.94
- 市盈率 静 10.04
- 换手率 824.45%
- 52周最低 4.14
- 委 比 30.80%
- 总股本 5.65万
- 历史最高 33.44
- 量 比 0.56
- 振 幅 4.92%
- 历史最低 1.10
- 每 手 1
- 风险率 1.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for February 23rd
VNDA: 54% | On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets, A First Line Therapy For The Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder And
02-23 20:20
Analyst Expectations For Vanda Pharmaceuticals's Future
In the last three months, 4 analysts have published ratings on Vanda Pharmaceut...
02-23 20:00
Earnings Outlook For Vanda Pharma
Vanda Pharma (NASDAQ:VNDA) is set to give its latest quarterly earnings report ...
02-11 04:01
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside
Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.
01-07 02:32
Nasdaq Moves Lower; US Crude Oil Inventories Decline Sharply
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
01-01 01:56
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight?
Vanda Pharmaceuticals' shares surged in after-hours trading following FDA approval of NEREUS for preventing motion-induced vomiting in adults.
2025-12-31 10:39
FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up
FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions.
2025-11-29 00:10
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.
2025-11-21 02:59
中信证券：首予阜博集团(03738)“买入”评级 目标价8港元 看好全球维持版权保护长期需求
中信证券发布研报称，看好阜博集团(03738)投资价值公司，首次覆盖，给予“买入”评级。预计公司2025-2027年收入分别为29.79/37.38/47.1...
2025-08-14 11:49
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets efficacy standards and plans to continue pursuing approval.
2024-09-19 22:33
